Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexpramipexole in Eosinophilic Asthma (EXHALE-4)
NCT05748600Phase 3Active, not recruiting
- Sponsor
- Areteia Therapeutics
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of dexpramipexole in eosinophilic asthma (EA), sponsored by Areteia Therapeutics. Started Jan 2023; status: active, not recruiting.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05748600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748600.